MHDL Updates

Below are certain updates to the MassHealth Drug List (MHDL). See the MHDL for a complete listing of updates.

1. **Additions**
   The following newly marketed drugs have been added to the MassHealth Drug List as of March 12, 2012.
   - Erwinaze (asparaginase *Erwinia chrysanthemi*)
   - fluoxetine 60 mg tablet
   - Jakafi (ruxolitinib)
   - ONFI (clobazam)

2. **New FDA “A”-Rated Generics**
   The following FDA “A”-rated generic drugs have been added to the MassHealth Drug List as of March 12, 2012. The brand name is listed with a # symbol, to indicate that prior authorization is required for the brand.
   - New FDA “A”-Rated Generic Drug
     - methylphenidate 20, 30 or 40 mg – PA > 60 units/month
     - fluocinolone oil, otic drops
     - piperacillin/tazobactam
   - Generic Equivalent
     - Ritalin LA #
     - DermOtic #
     - Zosyn #

3. **Change in Prior-Authorization Status**
   a. The following drug requires prior authorization when exceeding quantity limits effective March 12, 2012.
   - Aricept # (donepezil 10 mg tablet) – PA > 60 units/month
   b. The following drug is covered without prior authorization effective March 12, 2012.
   - Vivitrol (naltrexone injection)
   c. The following drugs will require prior authorization when exceeding quantity limits effective March 26, 2012.
   - Spiriva (tiotropium) – PA > 30 units/month
   d. The following antidiarrheal agents will require prior authorization effective March 26, 2012.
   - opium tincture – PA
   - Motofen (atropine/difenoxin) – PA

4. ** Corrections**
   a. The following drugs have been added to the MassHealth Drug List. They were omitted in error. These changes do not reflect any change in MassHealth policy.
   - Atralin (tretinoin)
   - chloral hydrate solution
   - Elspar (asparaginase)
   - erythromycin, topical – PA > 22 years
   - fenofibric acid tablet 35 mg and 105 mg
   - Ifex (ifosfamide)
   - Oncaspar (pegasparaginase)
   - Questran Light # (cholestyramine/aspartame)

   b. The prior-authorization status of the following drug has been clarified. These changes do not reflect any change in MassHealth policy.
   - Evoclinc (clindamycin foam)

   ^ This drug is available through the health care professional who administers the drug. Medicaid does not pay for this drug to be dispensed through a retail pharmacy.

**Reminder about Claims Processing When MassHealth is a Secondary Insurer**

When a pharmacy is not a participating provider for a MassHealth member’s primary insurance, or the pharmacy receives a message from the primary insurer that a product is covered only at certain network pharmacies, the pharmacy cannot appropriately bill MassHealth as the primary payer using Other Coverage Code 3.

In these instances, the pharmacy must instruct the member that they need to use a participating pharmacy of the primary insurer.

Please direct any questions or comments (or to be taken off this fax distribution) to Victor Moquin of ACS at 617-423-9830.